drugset / Trial / NCT00239278

Budesonide / Formoterol in Treatment of Exacerbations of COPD

NCT00239278

Phase 2 Completed 120 enrolled AstraZeneca
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to determine whether the budesonide+formoterol combination is effective in the treatment of exacerbations of COPD with a main emphasis on investigating the effects on inflammation and a secondary emphasis on clinical efficacy

Timeline

Start
2001-01
Primary completion
Completion
2005-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Budesonide Small molecule 400 ug Inhaled
Subject Formoterol Other / unclassified 12 ug Inhaled
Subject Prednisolone Other / unclassified 30 mg Oral